Cardiac FailureECMO-POPNCT07334457
Study of Platelet Population Changes Under Circulatory Support With ECMO
An observational study of Cardiac Failure and Respiratory Failure, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Failure, Respiratory Failure
- How many people
- 75 participants
- Where
- 1 siteFrance
- Study dates
- 11 Mar 2025to 11 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: - Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital and implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.
Who may be able to join
- Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital.
- Implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.
Who cannot join
- Subject who has expressed their opposition to participating in the study.
- Subject under legal protection.
- Subject under guardianship or curatorship.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service d'anesthésie-réanimation - CHU de Strasbourg - France
Strasbourg, 67091
Charles TACQUARD, MD, PhD, 33.3.69.55.16.08, charlesambroise.tacquard@chru-strasbourg.fr
Charles TACQUARD, MD, PhD
About this study
Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.
- Conditions
- Cardiac Failure, Respiratory Failure
- Keywords
- Cardiac Failure, Respiratory Failure
- Medical subject headings
- Heart Failure, Respiratory Insufficiency
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic)
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) on Days 1, 3, and 7 after the initiation of ECMO treatment.
Measured: Days 1, 3, and 7 after the initiation of ECMO treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start11 Mar 2025
- Primary completionMar 2027 (estimated)
- Study completion11 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07334457
- Sponsor's protocol ID
- 9614
- Acronym
- ECMO-POP
- Status last verified
- Dec 2025
- First submitted
- 30 Dec 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Platelet Population Changes Under Circulatory Support With ECMO
- ClinicalTrials.gov ID
- NCT07334457
- Acronym / sponsor ID
- ECMO-POP / 9614
- Conditions
- Cardiac Failure, Respiratory Failure
- Keywords
- Cardiac Failure, Respiratory Failure
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 11 Mar 2025 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- 11 Mar 2027 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- - Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital and implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.
Key inclusion criteria (2 listed)
- Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital.
- Implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.
Key exclusion criteria (3 listed)
- Subject who has expressed their opposition to participating in the study.
- Subject under legal protection.
- Subject under guardianship or curatorship.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic)
Time frame: Days 1, 3, and 7 after the initiation of ECMO treatment.
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) on Days 1, 3, and 7 after the initiation of ECMO treatment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
Related trials for Cardiac Failure
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 3
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
Acute Heart Failure
Recruiting
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
Atrial Fibrillation (Paroxysmal), Hypertension
Recruiting
Laser Acupuncture for Fatigue in Hemodialysis Patients
ESRD (End Stage Renal Disease), Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiac Failure and Respiratory Failure, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charles TACQUARD, MD, PhD (33.3.69.55.16.08, charlesambroise.tacquard@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) (time frame: Days 1, 3, and 7 after the initiation of ECMO treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.